MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics

Many pathogenic variants implicated in Mendelian diseases impair normal protein function, often through loss-of-function effects, while loss-of-function mutations in tumor suppressor genes commonly contribute to tumorigenesis. However, many disease-causing variants act through gain-of-function or other mechanisms that do not strictly disrupt the protein. Interpreting rare and novel variants remains a major challenge in clinical genomics, highlighting the need for computational tools informed by large, well-curated clinical datasets to reliably distinguish truly deleterious mutations from neutral variation. We developed MutAnt, a mutation meta‑annotator based on machine‑learning. It is trained on a large, clinically relevant dataset of variants using multiple variant properties, including synchronised predictions from other algorithms. MutAnt models demonstrate high F1 and ROC‑AUC scores (0.88-0.99) on hold‑out datasets and provide well‑calibrated probability scores that correlate with functional assays. MutAnt's deleteriousness predictions exhibited correlations with functional scores obtained from deep mutational scanning assays for tumor suppressor proteins BRCA1, PTEN, and p53 (ρ = 0.28-0.61), and with protein stability measurements from computational models. Moreover, MutAnt prediction scores of deleteriousness improved somatic variant calling from RNA sequencing data compared to standard approaches. MutAnt's high performance in distinguishing neutral and protein-disrupting mutations highlights its potential clinical utility in variant classification.

Authors

Institutions

Publication Details

Journal
Human Genetics
Published
2025-12-01
DOI
https://doi.org/10.1007/s00439-025-02775-5
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics

Zoya Antysheva, Marina A. Pak, Max Feinberg, Miryam Spektor et al.
Human Genetics
Genomics and Rare Diseases
article

MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics

Zoya Antysheva, Marina A. Pak, Max Feinberg, Miryam Spektor, Linda Balabanian, Nathan Fowler, Alexander Bagaev, Anastasiya Yudina, Aleksandr Sarachakov, Anna Parfenenkova, Viktor Svekolkin, Jessica H. Brown, Polina Oshchepkova
article en

Abstract

Many pathogenic variants implicated in Mendelian diseases impair normal protein function, often through loss-of-function effects, while loss-of-function mutations in tumor suppressor genes commonly contribute to tumorigenesis. However, many disease-causing variants act through gain-of-function or other mechanisms that do not strictly disrupt the protein. Interpreting rare and novel variants remains a major challenge in clinical genomics, highlighting the need for computational tools informed by large, well-curated clinical datasets to reliably distinguish truly deleterious mutations from neutral variation. We developed MutAnt, a mutation meta‑annotator based on machine‑learning. It is trained on a large, clinically relevant dataset of variants using multiple variant properties, including synchronised predictions from other algorithms. MutAnt models demonstrate high F1 and ROC‑AUC scores (0.88-0.99) on hold‑out datasets and provide well‑calibrated probability scores that correlate with functional assays. MutAnt's deleteriousness predictions exhibited correlations with functional scores obtained from deep mutational scanning assays for tumor suppressor proteins BRCA1, PTEN, and p53 (ρ = 0.28-0.61), and with protein stability measurements from computational models. Moreover, MutAnt prediction scores of deleteriousness improved somatic variant calling from RNA sequencing data compared to standard approaches. MutAnt's high performance in distinguishing neutral and protein-disrupting mutations highlights its potential clinical utility in variant classification.

Human GeneticsVol. 144(11-12)
Addgene (US), Institute of Molecular and Cell Biology (RU), Repligen (United States) (US)
Openalex Percentile: Top 60%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.